Inflammatory bowel diseases are chronic afflictions, characterized by active and remission periods. Inflammation is the most common type of response that the human body uses as a defense mechanism against aggressors from the environment. The frequency and degree of inflammation depends on the size of the affected tissues. The gastrointestinal tract is, by far, the most susceptible tissue to inflammatory responses, because of its constant exposure to various antigenic, mutagenic and toxic factors.
In inflammatory bowel diseases there is a loss of immune tolerance to intestinal flora that is mediated by various substances, including cytokines.Cytokines represent a key signal in the intestinal immune response. Activated dendritic cells and macrophages secrete cytokines that actively intervene in inflammation regulation, in both Crohn's disease and ulcerative colitis. After their secretion by antigen presented cells, cytokines activate and differentiate T cells, stirring up the adaptive immune response.
Cytokines have an important role in the pathogenesis of inflammatory bowel diseases. The identification of new cytokines, as well as the changing of the pathogenesis paradigms in inflammatory bowel diseases has been done on animal tests and clinical studies. Thus, there is promising evidence basis for future therapy research based on cytokines, and anti-cytokine antibodies.
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Inflammatory bowel diseases (IBD) are chronic afflictions, characterized by active and remission periods. The IBD entity includes three forms of disease: Crohn's Disease (CD), Ulcerative Colitis (UC) and Indeterminate Colitis. As of this moment, the pathogenesis of this group of diseases is not fully understood.
Inflammation is the most common type of response that the human body uses as a defense mechanism against aggressors from the environment. The frequency and degree of inflammation depends on the size of the affected tissues. The gastrointestinal tract is, by far, the most susceptible tissue to inflammatory responses, because of its constant exposure to various antigenic, mutagenic and toxic factors. Even in normal conditions, the intestinal mucosa is in a state of "physiologic inflammation", manifested by the abundance of leukocytes in the intraepithelial and subepithelial compartments [1] [2] . This is the consequence of an immune response to bacterial antigens and antigens in food. This concept has led to the idea that the bowel represents the largest lymphoid organ in the human body [1] [3] .
There is, also, a real inflammatory response (what could be called "pathological inflammation"), dominated by cells of the immune system from the intestinal mucosa. According to this theory, the active immune cells, represented by the neutrophils, macrophages and cytotoxic T-cells act as aggressors that attack and destroy the cells in the vicinity, either by direct contact or indirectly by releasing soluble factors like reactive oxygen species or nitric metabolites, cytotoxic proteins, lytic enzymes or cytokines [1] [4] [5] .
There are two response models for the nonimmune cells of the intestinal mucosa:
1. A unidirectional model, where all nonimmune cells of the mucosa are passive, waiting to be damaged and eventually die as a result of the actions of effector immune cells [1] (Fig. 1 [7] . The multidirectional model of interference between effector cells and target cells is probably the most realistic and can best explain the mechanism of chronic inflammation of the bowel in IBDs [1] (Figure 2) . Thus, the reactive behavior of non-immune cells can be explained. This causes symptoms and clinical modifications like pain, changes in intestinal motility, fibrous structures, fistulas, intestinal occlusion or neoplastic transformation.
In IBDs there is a loss of immune tolerance to intestinal flora that is mediated by various substances, including cytokines.
Cytokines represent a key signal in the intestinal immune response. Cytokines are small peptides produced by immune cells that have the role of transmitting intercellular signals, the stimulation of cell proliferation for the antigen specific effector cells and the autocrine, paracrine and endocrine mediation of local and systemic inflammation. Activated dendritic cells and macrophages secrete cytokines that actively intervene in inflammation regulation, in both CD and UC. After their secretion by antigen presented cells (APCs), cytokines activate and differentiate T cells, activating the adaptive immune response. UC is characterized by the production of IL-13 by the natural killer T (NKT) CD1 cells, and by the production of cytokines by Th2 cells [9] . It appears that UC is a disease mediated by Th2 cytokines and is characterized by an increase in production of IL-5 and a normal production of INF-γ [12] [13] [14] . In contrast, the production of IL-4 by Th2 cells was not increased in UC, which leads to the conclusion that it is a "Th-2 like" disease, rather than a true Th2 disease. NKT cells that produce IL-13 and IL-5 are the effectors of the main response [14] ( Figure 4 ).
PRO-INFLAMMATORY CYTOKINES
TUMOR NECROSIS FACTOR α Lymphocytes and APCs are responsible for the inflammation in IBDs, especially by increasing the production of the Tumor Necrosis Factor α (TNF-α).
TNF-α is produced by macrophages, monocytes and differentiated T cells. It has a proinflammatory effect through an increased production of IL-1β and IL-6, the expression of adhesion molecules, the proliferation of fibroblasts and procoagulant factors and the initiation of the acute response, cytotoxic and apoptotic phases, but also the inhibition of apoptosis [15] [16] . The expression of TNF-α has been identified in the colonic tissues and macrophages in both CD and UC [17] . The serum levels of TNF-α correlates with the presence of clinical and biological elements that indicate the activity of the intestinal disease [18] . Clinical studies have shown an important improvement in patients with CD, after the administration of anti-TNF-α therapy, like infliximab, adalimumab or certolizumab pergola [19] . The signaling pathway of TNF-α uses two serum soluble receptors, TNF receptor type I and II (STNF-RI, STNF-RII). The levels of these receptors correlate well with disease activity in IBD patients. More precisely, sTNF-RI up-regulates in the serum of IBD patients, compared to the healthy controls, and could potentially be used as a marker for disease activity [20] . The levels of sTNF-RII are significantly higher in patients with CD compared to patients with UC and could be used as an extra parameter for the differentiation between the two diseases [9] [19] .
However, the activation of the STNF-RI based immune response was recently shown on animal models to reduce the mortality associated with intestinal lesions [21] . TL1A appears to stimulate the secretion of INF-γ through the stimulation of Th1 cells. A larger percentage of lymphocytes express the DR3 receptor for TL1A, in biopsies taken from afflicted bowel areas in CD and UC patients, and an increased synthesis of INF-γ has correlated with disease severity in IBD patients [22] .
The studies performed on mice suggest that TL1A is a co-stimulating cytokine that optimizes the Th1 and Th17 responses, inducing inflamemation [14] . Its pro-inflammatory effect affects both Th1/Th17 and Th2 cells. This dichotomy augments both types of T cell response. Studies performed on animals regarding TL1A are consistent with what is found in IBDs. Increased levels of TL1A have been shown in both CD and UC [22] [23] [24] [25] . CD14+ macrophages in CD produce large quantities of TL1A, which will determine an increase in INF-γ and IL-17.
It appears that TL1A produces an augmentation of the inflammatory effect more than the induction of an inflammatory effect as its primary mechanism. The polymorphism of TL1A genes is associated with an increased risk for CD [26] . INTERLEUKIN 1 Interleukin 1 (IL-1) along with TNF-α is important in the pathogenesis of IBD due to its upregulatory and pro-inflammatory activity. The IL-1 system is formed mainly by IL-1α and IL-1β, both of which induce the production of type 2 cyclooxygenase, phospholipase A and inducible nitric oxide synthase (iNOS) [27] . The tissular level of IL-1 was found to be significantly increased in UC patients compared to control [28] .
The IL-1 system also includes antagonists of the IL-1 receptors (IL-1Ra), as a control mechanism. In UC, IL-1, IL-1Ra and the Transforming Growth factor β1(TGFβ1) influence the size and time length of the inflammatory process. The IL-1Ra/ IL-1 ratio has frequently been used as a predictor of inflammation of the mucosa, however the level of IL-1, rather than the level of IL-1Ra or the ratio IL-1Ra/IL-1 correlates best with the degree of severity of inflammation [28] .
IL-1Ra inhibits IL-1 only in severely inflamed tissues of IBD patients while TGFβ1's controlling effect on inflammation has been more obvious in mild cases of UC [28] . INTERLEUKIN 6 Interleukin 6 (IL-6) performs its pro-inflammatory action by means of the IL-6 soluble receptor (sIL-6R). The combination of the soluble receptor IL-6 (sIL-6R) and IL-6 plays an important role in the multiple immunological reactions that appear in IBD and the levels of IL-6 and of sIL-6R can correlate with multiple clinical manifestations that appears in CD and UC, including fibrogenesis [9, [29] [30] [31] [32] .The peripheral immune cells, colonic epithelial cells and cells from the lamina propria along with an active form of the IL-6/STAT3 system could be responsible for the strong correlation with the degree of mucosa inflammation [33] .
STAT-3 induces anti-apoptotic factors like Bcl-2 and Bcl-xL, resulting in increased T cell resistance to apoptosis. This cycle of T cell accumulation, mediated by the resistance to apoptosis finally leads to chronic inflammation [34] . Blocking the IL-6 signaling pathway leads to the apoptosis of T cells, which shows that the IL-6 -sIL-6R system mediates the resistance of T cells to apoptosis in CD [32, 34] . Anti sIL-6R antibodies have been shown to reduce the levels of INF-γ, TNF-α and IL-1β mRNA and have suppressed the expression of several intercellular adhesion molecules in the colonic vascular endothelium [35] [36] . The IL-6/ STAT3 signaling in the activation of T mucosal cells has been suggested as a therapeutic target for the future [37] . INTERLEUKIN 18 Interleukin 18 (IL-18) is produced by intestinal epithelial cells and has been initially identified as an IFN-γ producing factor. It has several similarities with the IL-1 family, including structure, action, receptor, signal transmission model and antiinflammatory action [38] .
The equilibrium between IL-18 and its natural inhibitor, Interleukin 18 Binding Protein (IL-18BP), can have a role in IBD pathogenesis [39] . An increase in the local production of IL-18 and IL18-BP has been shown in chronic lesions compared to control in CD [40] , but the increase in IL18-BP is insufficient to control inflammation [39] .
The IL-12 cytokine can act synergic with IL-18 to promote the production of INF-γ, causing severe inflammation of the intestine [41] . The development of Th1 CD4+ cells in the intestinal mucosa is induced by IL-12 produced by activated macrophages and IL-18 produced by activated macrophages and colonic epithelial cells. The synergic effect is caused by up-regulation mechanism of the receptor for IL-18 by IL-12 [42] .
IL-18 may play a key role in Th1 mediated disorders, including CD, and thus, there could be a rationale for an anti-IL-18 based therapy [40] . INTERLEUKIN 17 Recently, a new type of T helper cell has been identified, called "Th17" and it is characterized by the production of Interleukin 17(IL-17) and has been identified as having an important role in inflammatory response [43] . Five other members of the IL-17 family have been identified, named IL-17B to IL-17F. IL-17A is exclusively produced in Th17 cells [44] .
IL-17 favorizes the production of multiple pro-inflammatory factors, including TNF-α, IL-6 and IL-1β, which has led to the conclusion that IL-17 has a very important role in the amplification and localization of inflammation [45] [46] [47] , as well as the process of fibrosis in CD [48] [49] . TNF-α and IL-6, both of which are produced by Th17 cells, not only sustain the development of Th17 cells, but also have a synergic action with IL-17 to increase the production of pro-inflammatory mediators [45] .
IL-17 as well as Th17 cells have been identified as having an increased serum and intestinal tissue level in IBD patients [50] . IL-17 has not been identified in the tissues of inactive patients or other types of colitis [51] . INTERLEUKIN 12 AND INTERLEUKIN 23 Interleukin 12 (IL-12) and Interleukin 23 (IL-23) belong to the IL-12 family of cytokines. They are produced mainly by activated APCs and other cells like dendritic cells and phagocytes [52] . IL-12 induces the production of INF-γ and the differentiation of Th0 cells into Th1 cells. It represents a link between innate resistance and adaptive resistance.
ANTI-INFLAMMATORY AND IMMUNOMODULATOR CYTOKINES

INTERLEUKIN 4
Interleukin 4 (IL-4) induces the differentiation of naive T helper cells (Th0 cells) to Th2 cells. A study on animal models has shown that treatment with anti IL-4 antibodies leads to increased INF-γ production and to the induction of a shift of Th2 cells to the Th1 type [53] .
Another study has shown that the administration of IL-4 determines a significant reduction in the increase of Vascular Endothelial Growth Factor (VEGF) that normally appears in the peripheral blood in CD and UC patients, suggesting that a defective immunosuppressive effect of IL-4 may contribute to the pathologic mechanism of IBD [54] . INTERLEUKIN 10 Interleukin 10 (IL-10) is a cytokine with antiinflammatory effects that inhibits both the antigen presentation and the subsequent release of proinflammatory cytokines. An inactivation of IL-10 in mice has led to the increased production of IL-12 and INF-γ [55] [56] . In CD with active inflamemation and granulomas, the IL-10 levels were found to be decreased.
Regulatory B cell subtype (Bregs cells) participate in the production of IL-10, and thus contribute to the anti-inflammatory effect and have a protective role [57] . It has been shown on animal models that transferring Breg cells in IL-10 deficient mice blocked the development of colitis [58] .
TRANSFORMATION GROWTH FACTOR β TGF-β as an inhibitor cytokine acts as a regulatory key for the inflammatory response. The decrease in TGF-β activity is considered responsible for the development of several autoimmune disorders, including IBDs [59] . Some evidence suggests that TGF-β acts by protecting the host tissues from the luminal aggressions and facilitates the repair of the mucosal lesions in IBD [60] [61] .
OTHER CYTOKINES WITH ROLES IN IBDS
Other cytokines, like IL-21 and IL-22, can play a role in the induction of IBDs as well as in other autoimmune diseases. INTERLEUKIN 21 Interleukin 21 (IL-21) acts on the intestinal epithelium, maintaining the inflammation induced by Th1 by induction of INF-γ production [62] [63] . It has been demonstrated that IL-21 increases the number of NK cells on a large scale [64] . IL-21 is expressed by T cells, B cells and non-immune cells, like fibroblasts. IL-21 contributes to the differentiation of Th17 cells [65] , with an over expression in both CD and UC [50] . The highest levels were identified in CD [66] . IL-21 also induces IL-22 synthesis in CD4+ T cells [67] . INTERLEUKIN 22 Interleukin 22 (IL-22) acts on subepithelial myofibroblasts and increases the production of proinflammatory cytokines and matrix-degrading molecules [68] . IL-22 has a pro-inflammatory role and is increased in both CD and UC [50] [69] [70] .
Surprisingly, it was shown that IL-22 has a protective role in IBDs, as it attenuates the intestinal inflammation, inducing the production of a mucine membrane by goblet cells [69] [70] [71] . Administration of anti-IL-22 antibodies and IL-22 knockout mice has shown delayed healing of colonic injuries [72] , while administration of IL-22 has led to a more rapid recovery in Th2-mediated colitis [70] . This makes IL-22 a promising future target for therapy.
Gene mutations involved in encoding IL-22 and the IL-10R2 subunit of the IL-22R complex have been found to be associated with IBD [73] [74] . Another recent paper showed that IL23R genotypes affect IL-22 serum concentrations, linking genetic CD susceptibility to Th17 function [69] .
CONCLUSIONS
Cytokines have an important role in the pathogenesis of IBDs. The identification of new cytokines, as well as the changing of the pathogenesis paradigms in IBDs has been done on animal tests and clinical studies. Thus, there is promising evidence basis for future therapy research based on cytokines and anti-cytokine antibodies.
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